Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sirolimus

FDA-approved product (solution, oral), marketed as Fyarro, Hyftor, Rapamune and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Angiofibroma
  • Cancer
  • Delayed Graft Function
  • Eye disease
  • Kidney transplant
  • Neoplasm
  • Tuberous sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors; Other ophthalmologicals
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

    NCT06876142 · start 2026-09-24

    Registered record
    Registry ID
    NCT06876142
    Conditions
    Multiple Myeloma; Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Interventions
    Mirdametinib; Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Suspended
    Start
    2026-09-24
    Completion
    2033-01-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Relapsed and/or Refractory Multiple Myeloma (RRMM)
    InterventionMirdametinib; Sirolimus
    PhasePhase 1 / Phase 2
    Registry statusSuspended

  • Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

    NCT07252050 · start 2026-06-08

    Registered record
    Registry ID
    NCT07252050
    Conditions
    Sickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation; Graft Failure
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-08
    Completion
    2029-11-19
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation +1 more
    InterventionRuxolitinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

    NCT07443826 · start 2026-06-01

    Registered record
    Registry ID
    NCT07443826
    Conditions
    Age-related Muscle Decline
    Interventions
    AAV9-Follistatin gene therapy; VEGF Plasmid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2028-06-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAge-related Muscle Decline
    InterventionAAV9-Follistatin gene therapy; VEGF Plasmid
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

    NCT07463664 · start 2025-04-28

    Registered record
    Registry ID
    NCT07463664
    Conditions
    Chronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    Interventions
    DES Implantation; DCB Angioplasty
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-28
    Completion
    2026-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    InterventionDES Implantation; DCB Angioplasty
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

    NCT06680921 · start 2024-11-14

    Registered record
    Registry ID
    NCT06680921
    Conditions
    Locally Advanced or Metastatic Breast Cancer
    Interventions
    SIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-11-14
    Completion
    2028-08-31
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Breast Cancer
    InterventionSIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
    PhasePhase 3
    Registry statusActive not recruiting

  • MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

    NCT05908331 · start 2024-04-16

    Registered record
    Registry ID
    NCT05908331
    Conditions
    In-Stent Restenosis; Cardiovascular Diseases; Coronary Artery Disease
    Interventions
    Sirolimus Drug Coated Balloon; Plan balloon Angioplasty (POBA)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-16
    Completion
    2028-07
    Enrolment
    492

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIn-Stent Restenosis; Cardiovascular Diseases; Coronary Artery Disease
    InterventionSirolimus Drug Coated Balloon; Plan balloon Angioplasty (POBA)
    PhaseNot applicable
    Registry statusRecruiting

  • Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial

    NCT06091332 · start 2024-01-05

    Registered record
    Registry ID
    NCT06091332
    Conditions
    Cavernous Malformations; Intracerebral Hemorrhage; Brainstem Stroke
    Interventions
    Sirolimus; Starch flake
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-05
    Completion
    2026-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCavernous Malformations; Intracerebral Hemorrhage; Brainstem Stroke
    InterventionSirolimus; Starch flake
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    NCT05918302 · start 2023-10-27

    Registered record
    Registry ID
    NCT05918302
    Conditions
    Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Interventions
    177Lu-edotreotide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-27
    Completion
    2029-10
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
    Intervention177Lu-edotreotide; Everolimus
    PhasePhase 3
    Registry statusRecruiting

  • The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

    NCT06550271 · start 2023-04-25

    Registered record
    Registry ID
    NCT06550271
    Conditions
    Aging
    Interventions
    Rapamycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-25
    Completion
    2023-12-15
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging
    InterventionRapamycin
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Loratadine in Lymphangioleiomyomatosis

    NCT05190627 · start 2021-11-01

    Registered record
    Registry ID
    NCT05190627
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    Loratadine; Placebo 10mg/day added to rapamycin for 12 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-11-01
    Completion
    2023-12-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    InterventionLoratadine; Placebo 10mg/day added to rapamycin for 12 months
    PhasePhase 2
    Registry statusUnknown

  • Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

    NCT05490095 · start 2021-07-23

    Registered record
    Registry ID
    NCT05490095
    Conditions
    Pharmacokinetics
    Interventions
    SVG101 (T); Afinitor (R)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-23
    Completion
    2022-02-07
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionSVG101 (T); Afinitor (R)
    PhasePhase 1
    Registry statusCompleted

  • Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

    NCT04177004 · start 2021-04-30

    Registered record
    Registry ID
    NCT04177004
    Conditions
    Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy; Goat Milk; Palifermin; Sirolimus; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-04-30
    Completion
    2026-10-27
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy +4 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia

    NCT04594889 · start 2020-10-14

    Registered record
    Registry ID
    NCT04594889
    Conditions
    Critical Limb Ischemia; Drug Effect
    Interventions
    angioplasty
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-10-14
    Completion
    2022-12-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Limb Ischemia; Drug Effect
    Interventionangioplasty
    PhaseNot applicable
    Registry statusUnknown

  • STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion

    NCT03563989 · start 2018-06-26

    Registered record
    Registry ID
    NCT03563989
    Conditions
    Chronic Total Occlusion; Coronary Artery Disease
    Interventions
    Implantation of Stent (PCI)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-06-26
    Completion
    2019-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Total Occlusion; Coronary Artery Disease
    InterventionImplantation of Stent (PCI)
    PhaseNot applicable
    Registry statusUnknown

  • Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

    NCT03263559 · start 2017-10-03

    Registered record
    Registry ID
    NCT03263559
    Conditions
    Sickle Cell Disease
    Interventions
    Haploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa; Fludarabine; Cyclophosphamide; Total Body Irradiation; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2025-01-29
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionHaploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa +4 more
    PhasePhase 2
    Registry statusCompleted